Kelly Cleland1, Jamie Bass2, Florida Doci3, Angel M Foster3. 1. Office of Population Research, Princeton University, Princeton, New Jersey; American Society for Emergency Contraception, Princeton, New Jersey. Electronic address: kcleland@princeton.edu. 2. American Society for Emergency Contraception, Princeton, New Jersey. 3. University of Ottawa, Ottawa, Ontario, Canada.
Abstract
INTRODUCTION: After years of complex regulatory changes, levonorgestrel (LNG) emergency contraception (EC) is now approved for unrestricted sale in the United States. Timely access to EC pills is critical because they are more likely to work the sooner they are taken. This study assesses whether LNG EC is sold in accordance with current Food and Drug Administration regulations. METHODS: We distributed an online questionnaire through an EC-focused listserv for reproductive health professionals, asking data collectors to visit local stores and document product names, price, over-the-counter shelf availability, and misinformation about age restrictions. We used χ2 analysis to assess bivariate associations and t tests and Wilcoxon rank-sum tests to determine differences in means. RESULTS: We collected information about 220 stores. The majority (65%) stocked EC on over-the-counter shelves, although only 22% of these displayed it without a locked security enclosure. Chain pharmacies were more likely to shelf-stock EC than independent pharmacies (77% vs. 5%; p = .000), but variation existed among stores within the same chain. Among stores that were asked, 40% incorrectly reported an age restriction for non-prescription purchase of LNG EC, whereas 95% correctly reported that men can buy LNG EC. The average price of branded and generic LNG EC was $49.64 and $40.05, respectively. CONCLUSIONS: Changes in the regulatory status of LNG EC have resulted in widespread confusion about how EC can be sold, and its high price contributes to access barriers. Retailers should ensure that consumers can access LNG EC quickly and easily by stocking the product on over-the-counter shelves and educating staff about current regulations.
INTRODUCTION: After years of complex regulatory changes, levonorgestrel (LNG) emergency contraception (EC) is now approved for unrestricted sale in the United States. Timely access to EC pills is critical because they are more likely to work the sooner they are taken. This study assesses whether LNG EC is sold in accordance with current Food and Drug Administration regulations. METHODS: We distributed an online questionnaire through an EC-focused listserv for reproductive health professionals, asking data collectors to visit local stores and document product names, price, over-the-counter shelf availability, and misinformation about age restrictions. We used χ2 analysis to assess bivariate associations and t tests and Wilcoxon rank-sum tests to determine differences in means. RESULTS: We collected information about 220 stores. The majority (65%) stocked EC on over-the-counter shelves, although only 22% of these displayed it without a locked security enclosure. Chain pharmacies were more likely to shelf-stock EC than independent pharmacies (77% vs. 5%; p = .000), but variation existed among stores within the same chain. Among stores that were asked, 40% incorrectly reported an age restriction for non-prescription purchase of LNG EC, whereas 95% correctly reported that men can buy LNG EC. The average price of branded and generic LNG EC was $49.64 and $40.05, respectively. CONCLUSIONS: Changes in the regulatory status of LNG EC have resulted in widespread confusion about how EC can be sold, and its high price contributes to access barriers. Retailers should ensure that consumers can access LNG EC quickly and easily by stocking the product on over-the-counter shelves and educating staff about current regulations.
Authors: Anna F Glasier; Sharon T Cameron; Paul M Fine; Susan J S Logan; William Casale; Jennifer Van Horn; Laszlo Sogor; Diana L Blithe; Bruno Scherrer; Henri Mathe; Amelie Jaspart; Andre Ulmann; Erin Gainer Journal: Lancet Date: 2010-01-29 Impact factor: 79.321
Authors: Sally Rafie; Jennifer McIntosh; Debra K Gardner; Kristen M Gawronski; Lamis R Karaoui; Erin R Koepf; Katherine Joy Lehman; Sarah McBane; Nima M Patel-Shori Journal: Pharmacotherapy Date: 2013-02-28 Impact factor: 4.705
Authors: Bernhard Langer; Sophia Grimm; Gwenda Lungfiel; Franca Mandlmeier; Vanessa Wenig Journal: Int J Environ Res Public Health Date: 2020-09-15 Impact factor: 3.390